Abstract
Among genito-urinary tumors, gemcitabine is indicated only for the treatment of locally advanced and metastatic urothelial cancer. The combination of gemcitabine and cisplatin is a new standard in this disease. Gemcitabine shows activity in refractory germ cell tumors. In salvage treatment its role is ongoing evaluation. The combination of gemcitabine and 5-fuoruracile has modest activity in renal cell carcinoma. Pemetrexed is not indicating in genitor-urinary tumors, further evaluation in urothelial cancer is warranted.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Clinical Trials as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Doxorubicin / administration & dosage
-
Gemcitabine
-
Glutamates / administration & dosage
-
Glutamates / therapeutic use*
-
Guanine / administration & dosage
-
Guanine / analogs & derivatives*
-
Guanine / therapeutic use
-
Humans
-
Kidney Neoplasms / drug therapy
-
Methotrexate / administration & dosage
-
Pemetrexed
-
Urologic Neoplasms / drug therapy*
-
Urologic Neoplasms / pathology
-
Vinblastine / administration & dosage
Substances
-
Glutamates
-
Pemetrexed
-
Deoxycytidine
-
Vinblastine
-
Guanine
-
Doxorubicin
-
Cisplatin
-
Methotrexate
-
Gemcitabine